AssetMark Inc’s Avidity Biosciences RNAM Stock Holding History

AssetMark Inc’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,967	Closed	-$430K	–	3570
2025 Q4	$430K	Sell	5,967 -45,219	-88%	-$2.92M	﹤0.01%	1154
2025 Q3	$2.23M	Buy	51,186 +21,507	+72%	+$869K	﹤0.01%	788
2025 Q2	$843K	Buy	29,679 +2,025	+7%	+$60.4K	﹤0.01%	961
2025 Q1	$816K	Buy	27,654 +15,093	+120%	+$470K	﹤0.01%	896
2024 Q4	$365K	Buy	12,561 +242	+2%	+$10.1K	﹤0.01%	1001
2024 Q3	$566K	Buy	+12,319	New	+$535K	﹤0.01%	878

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

AssetMark Inc's RNAM Position: Q1 2026 in Review

AssetMark Inc sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 5,967 shares — an estimated $430K sold.

AssetMark Inc first reported a position in RNAM in Q3 2024 and held it in 6 quarters. The position peaked at $2.23M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

AssetMark Inc reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
AssetMark Inc sold 5,967 Avidity Biosciences shares in Q1 2026, an estimated $430K.
AssetMark Inc first reported a position in Avidity Biosciences in Q3 2024 and held it in 6 quarters.
AssetMark Inc's Avidity Biosciences position peaked at $2.23M in Q3 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.